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Abstract
Primary IgA nephropathy (IgAN) is characterized by mesan-
gial deposits of IgAl, increased serum IgAl levels, and circu-
lating immune complexes containing predominantly IgAl. It
has previously been found that patients with IgAN have a
higher than normal IgA response to vaccination, but the IgA
subclasses have not been studied. To investigate whether the
IgA hyperresponsiveness is limited to the subclass IgAl,
which is involved in the pathogenesis of IgAN, we compared
the immune responses of 18 patients with 22 healthy controls
after intramuscular vaccination with inactivated influenza
virus. Antibody titers were significantly higher (P < 0.0001)
for the IgAl subclass in patients versus controls, but not for
the other isotypes. A substantial portion of the IgA and IgAl
antiinfluenza immune response comprised polymers in both
patients and controls. There was no preferential response of
polymers in patients. Patients produced significantly more
monomeric IgAl antibodies than controls. These results show
that patients with IgAN have a hyperresponsiveness limited
to the subclass IgAl and mainly expressed by an excess of
monomers.
Introduction
Primary IgA nephropathy (IgAN)' has been found to be the
most common form of primary glomerulonephritis in all
countries where adequate epidemiological data have been ac-
quired (1). The disease is characterized by mesangial deposits
ofIgA, and there is now widespread agreement that the mesan-
gial IgA contains almost exclusively the subclass IgA 1 (2-8).
Patients with IgAN have increased IgA plasma levels (4, 9-1 1).
This increase in IgA was recently found to be due to elevated
levels of IgA 1 (i2-14). Circulating immune complexes in
IgAN also contain predominantly the subclass IgAl (7, 15, 16).
A shift in the IgA subclass distribution toward IgA I has re-
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1. Abbreviations used in this paper: IgAN, primary IgA nephropathy;
NBCS, newborn calf serum; VBS, Veronal-buffered saline.
cently been found in the Ig produced by peripheral blood lym-
phocytes (14), and in the plasma cells in the bone marrow (17)
and tonsils (18) of patients with IgAN. From these data it
becomes evident that the biological abnormalities in the IgA
system in patients with IgAN are predominantly or exclusively
restricted to the subclass IgA 1.
The pathogenetic significance of polymeric IgA in IgAN is
a subject ofcontroversy. The mesangial deposits were found to
contain polymeric IgA by some investigators (7, 19-21), but
not by others (2, 5, 6, 8). In the plasma, polymeric IgA was
found to be elevated in two studies (7, 22), but no absolute (I 1,
23, 24) or relative (6, 12, 13, 25, 26) increase was found by
others. These conflicting results can be partially explained by
the fact that elevated serum levels of polymeric IgA are found
predominantly during attacks of macroscopic hematuria (26).
In recent studies predominantly monomeric IgA was found in
the circulating immune complexes (6, 16, 27).
The elevated serum levels of IgA presumably are the result
of increased synthesis. A few studies have addressed the ques-
tion of whether patients with IgAN have a higher than normal
serum IgA immune response upon immunization. Parenteral
immunization with inactivated influenza virus (28) and
mumps virus (29) may lead to higher serum IgA responses in
patients with IgAN. However, in the study with influenza virus
no significant difference between patients and controls was
reported (28). In the study with mumps virus the titers ofIgAN
patients were not significantly different from those in healthy
controls, but they were significantly higher than the titers in
patients with IgM glomerulonephritis (29). Oral immunization
with polio vaccine resulted in significantly higher antigen-spe-
cific serum IgA responses in patients than in controls (30).
However, none of these studies measured the subclass distri-
bution and molecular size of the antigen-specific IgA. In view
of the above-mentioned restriction of the abnormalities to the
IgAl subclass in IgAN, and the possible pathogenic role of
polymers, the level and size of specific IgA1 antibodies were
studied in patients with IgAN and in healthy controls after
parenteral vaccination against influenza. Patients with IgAN
were found to be hyperresponsive only for the IgAl isotype.
However, the relative contribution of polymeric IgA1 to the
total amount of antigen-specific IgA1 was not different from
controls.
Methods
Patients and controls. The study protocol was approved by the ethical
committee of Leiden University Hospital, and all individuals gave
informed consent. 18 patients (14 males and 4 females with a mean age
of 36.0 yr; range, 24-78 yr) with biopsy-proven IgAN were studied.
None of the patients had clinical or laboratory evidence of Henoch-
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Schoenlein purpura, systemic lupus erythematosus, or liver disease.
Kidney function was normal in 13 patients. Mild to moderate renal
insufficiency (creatinine clearance 30-84 ml/min) was present in five
patients. As controls we used 22 healthy hospital employees, 16 males
and 6 females, with a mean age of 32.9 yr (range 24-54 yr). Neither
patients nor controls had clinical symptoms of mucosal infections in
the 2 wk preceding the study.
Vaccination. All individuals received a single vaccination by intra-
muscular injection of inactivated split virus influenza vaccine con-
taining A/Singapore/6/86 (H INI) (Vaxigrip; Institut Merieux, Lyon,
France) within a 2-wk period in December 1986. Serum samples were
obtained immediately before vaccination and at weekly intervals there-
after for a period of 5 wk. The absence of naturally occurring influenza
in The Netherlands during the study period was confirmed by epidemi-
ological monitoring. A total of 6 serum samples, from the theoretical
total of 240, were not available for study. No macroscopic hematuria
was noted in any of the patients during the study period.
ELISA. Isotype- and subclass-specific serum antibody responses
against A/Singapore/6/86 influenza virus were measured by ELISA.
The antigen was prepared by growing A/Singapore/6/86 in the allan-
toic cavity of embryonated eggs. The allantoic fluid was harvested,
diluted 1:4 in PBS, and the virus inactivated with 0.1 mg/ml Merthio-
late. The fluid was clarified by centrifugation at 2,000 g for 10 min at
4°C. The allantoic fluid was further diluted 1:10 with Veronal-buffered
saline (VBS), pH 7.4, containing 10% sucrose. The virus was sedi-
mented by ultracentrifugation at 100,000 g for 90 min at 20°C. The
pellet was resuspended in VBS-sucrose using a syringe and 19-gauge
needle. The ultracentrifugation step was repeated and the purified
virus was stored in VBS-sucrose in small aliquots at -70°C. Flat-bot-
tomed polystyrene microtiter plates (Titertek; Flow Laboratories,
Zwanenburg, The Netherlands) were coated with an optimal dilution
of the virus in carbonate buffer, pH 9.6, for 2 h at 37°C. In the ELISA
measuring the IgA subclasses, nonspecific binding sites were then
blocked by incubation with PBS containing 0.05% Tween 20 and 5%
heat-inactivated newborn calf serum (NBCS) for 2 h at 37°C. The
plates were washed with PBS-Tween three times. Samples were diluted
in PBS-Tween containing 1% NBCS and incubated in the virus-coated
wells overnight at room temperature. After three washes with PBS-
Tween, bound antibodies were detected with isotype-specific murine
MAbs applied for 2 h at 37°C. For the detection of IgM we used the
biotin-conjugated MAb HB57, and for IgG we used the biotin-conju-
gated MAb HB43 (American Type Culture Collection, Rockville,
MD). IgA was detected with a biotin conjugate of the MAb NI 69
(Nordic Immunological Laboratories, Tilburg, The Netherlands). IgA
subclasses were detected with the MAbs NI 69-11 (anti-IgA I) and NI
512 (anti-IgA2) (Nordic Immunological Laboratories), followed by
biotin-coupled goat anti-mouse IgG. After three washes with PBS-
Tween, streptavidine conjugated to horseradish peroxidase (Zymed,
Sanbio B.V., Uden, The Netherlands) in PBS-Tween-NBCS was ap-
plied to the wells for I h at 37°C. The wells were washed three times
with PBS-Tween, and substrate (o-phenylenediamine; Sigma Chemi-
cal Co., St. Louis, MO) conversion was read at 492 nm according to
conventional methods.
All antiinfluenza titers are expressed in arbitrary units per milli-
liter, relative to a standard serum yielding high OD values in the ELISA
for a certain isotype. A different standard serum was chosen for each
isotype, and this standard serum was used in a dilution series on each
ELISA plate. The standard sera yielded increasing OD values in a
dose-dependent fashion to values of at least 1.000, and usually
> 2.000. For the isotypes IgM, IgG, and IgA, the titer assigned to the
standard serum was 1,000 U/ml. The two IgA subclasses were mea-
sured relative to a single strongly positive serum with arbitrary titers of
8,000 U/ml of IgAl and 2,000 U/ml of IgA2. Sample titers were
calculated from the standard curves thus obtained. Blank values, ob-
tained on each plate using PBS-Tween-NBCS, were usually < 0.050,
and were subtracted from the OD values of standards and samples.
Calculations were made at sample dilutions yielding an OD in the
lower steep part of the curve.
To exclude an artifact in the IgA I antiinfluenza ELISA due to the
possible presence of IgA 1 rheumatoid factor in the sera, as has been
reported by other investigators (16), we performed a control experi-
ment using absorption to immobilized IgG. The sera obtained on days
0 and 14 were diluted 1:5 in PBS-Tween-NBCS, and a 500-pd sample
was incubated for 1 h at room temperature with 1 ml (packed volume)
of an immunoabsorbent of human IgG coupled to Biogel A5 (Bio-Rad
Laboratories B.V., Utrecht, The Netherlands). For comparison, the
diluted sera were incubated in a parallel fashion with a control im-
munoabsorbent. After separation of the absorbed samples from the
immunoabsorbent by centrifugation the samples were tested for IgA 1
antiinfluenza in the ELISA mentioned above. Separate experiments
demonstrated that the absorption technique used was capable of con-
sistently removing > 95% of the IgA I rheumatoid factor from two
strongly positive sera from patients with rheumatoid arthritis. The titer
of IgA 1 antiinfluenza antibodies was not reduced in either the patients
or the controls when comparing the IgG absorption with the control
absorption. This demonstrates that the presence of IgAl rheumatoid
factor does not influence the results in the IgA 1 antiinfluenza ELISA in
any significant way.
HPLC. The size distribution ofthe influenza-specific IgA was stud-
ied using molecular sieving HPLC. The sera obtained on days 14 and
28 were diluted 1:20 with 0.1 M phosphate buffer with 0.1 M NaCl (pH
6.8) and passed through a 0.22-Mm filter (Millipore/Continental Water
Systems, Bedford, MA). 200 ul ofeach sample was then injected onto a
TSK G3000 SW column connected via a guard column to an HPLC
pump (LKB, Bromma, Sweden). The column was equilibrated and
run in 0.1 M phosphate buffer with 0.1 M NaCl, pH 6.8, at a flow rate
of 0.3 ml/min. 1-min fractions were collected and assayed for total IgA
content using the ELISA previously described (17). Based on the IgA
elution profile thus obtained, fractions were pooled to form polymeric
and monomeric pools for each HPLC run. The volume for each pool
was determined by multiplying the number of fractions with the mean
fraction volume measured in each HPLC run. In each pool the titer of
influenza-specific IgA and IgAl was determined with the ELISA de-
scribed above. The amount of antigen-specific IgA2 in the HPLC pools
proved to be too low for detection by the ELISA. The total number of
polymeric and monomeric units in each sample was determined by
multiplying the titer with the pool volume. The percentage of poly-
meric IgA and IgA I was calculated by dividing the polymeric units by
the sum ofpolymeric and monomeric units. Two sera from the patient
group and one control serum were not available for study. Conse-
quently, the analysis was performed on 16 patients and 21 controls.
Data analysis. All data are expressed as arithmetic means±SEM.
The data were analyzed by two-way analysis of variance to study the
effect ofboth group (patient versus control) and time after vaccination.
For the serum titers and the units of influenza-specific antibody in the
polymeric and monomeric pools, this analysis of variance was per-
formed on their logarithmic values to normalize the data distribution.
The isotype ratios in individual sera and the percentage ofpolymers in
the HPLC study were calculated from the nontransformed data. Sta-
tistical analysis was performed with the Statgraphics software package
(STSC Inc., Rockville, MD).
Results
Isotype-specific serum immune response. The logarithmically
transformed titers of IgM, IgG, IgA, IgAI, and IgA2 antiin-
fluenza antibodies are plotted against time after vaccination in
Figs. 1 and 2. Analysis of variance revealed a significant (P
< 0.0001) increase in the IgM antiinfluenza titer after vaccina-
tion. The IgM response, however, did not differ between pa-
tients and controls (P = 0.36). IgG antiinfluenza titers also
increased significantly after vaccination (P < 0.0001), with no
significant difference between patients and controls (P = 0.31).
A significant (P < 0.0001) increase was also found for the IgA
antiinfluenza titers in time, and although patients had a higher
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Figure 1. Plot of the
IgM, IgG, and IgA an-
tiinfluenza titers, trans-
formed to their natural
logarithms, versus time
after immunization.
Solid line, mean re-
sponse in patients (n
= 18); dashed line, con-
trols (n = 22); vertical
bars, SEM. (Top) IgM
immune response;
(middle) IgG response;
(bottom) IgA response.
Patients were not signif-
icantly different from
controls for IgM (P
= 0.36) or IgG (P =
0.31). The difference
between patients and
controls was marginally
significant for IgA (P =
0.058).
immune response, the difference with healthy controls was not
statistically significant at the 0.05 level (P = 0.058). The IgAl
antiinfluenza titers also increased significantly after immuni-
zation (P = 0.001). The IgA 1 immune response was markedly
higher in patients than in healthy controls (P < 0.0001). The
peak ofthe IgA 1 antiinfluenza also appeared to occur earlier in
patients (day 7) than in controls (day 14). For the subclass
IgA2 a significant increase in the titers after immunization was
also found (P < 0.0001), with no significant difference between
the two groups (P = 0.44).
Isotype ratios of the immune response. The ratio of the
titers of IgA and IgG antiinfluenza antibodies was calculated
for each serum sample. Two-way analysis of variance demon-
strated a significantly higher (P = 0.01) IgA/IgG ratio in the
patients than in the controls. The influenza-specific IgA/IgG
ratio did not change significantly over the weeks after vaccina-
tion (P = 0.49). The ratio of the IgA titer over the sum of the
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Figure 2. Plot of the
IgAl and IgA2 antiin-
fluenza titers, trans-
formed to their natural
logarithms, versus time
after immunization.
Solid line, mean re-
sponse in patients (n
= 18); dashed line, con-
trols (n = 22); vertical
bars, SEM. (Top) IgAl
immune response; (bot-
tom) IgA2 response. Pa-
tients had a signifi-
cantly higher IgA I an-
tiinfluenza response
than controls (P
< 0.0001). The IgA2 re-
sponse was not signifi-
cantly different from
controls (P = 0.44).
titers of the isotypes IgA, IgG, and IgM was also significantly
higher in patients than controls (P = 0.039). This ratio did not
vary significantly over time (P = 0.26).
The ratio ofthe IgA 1 antiinfluenza titer over the sum ofthe
IgA 1 and IgA2 titers was also calculated for each serum sam-
ple. This ratio was significantly higher (P < 0.0001) in patients
than in controls. The IgA subclass ratio also changed signifi-
cantly over time after vaccination (P < 0.0001). This was due
to the fact that the mean IgAl response reached its peak value
at an earlier time (day 7) than the mean IgA2 response (day
14), especially in the patient group.
HPLC size analysis of the influenza-specific IgA. Data
from the HPLC study of the sera obtained on days 14 and 28
after vaccination are summarized in Table I. Polymeric IgA
antiinfluenza was not found to be significantly different be-
tween patients and controls (P = 0.94) in a two-way analysis of
variance. This was also the case for polymeric IgA 1 antiin-
fluenza antibodies (P = 0.19). Monomeric IgA antiinfluenza
was not higher in patients than in controls (P = 0.28). How-
ever, the influenza-specific monomeric IgA 1 was significantly
higher in patients with IgAN than in healthy controls (P
= 0.035). With respect to the effects of time after immuniza-
tion, the analysis of variance showed the polymeric IgA an-
tiinfluenza to be significantly higher on day 14 than 28 (P
= 0.009). The differences between days 14 and 28 were not
significant for polymeric IgA 1 (P = 0.21), monomeric IgA (P
= 0.13), or monomeric IgA 1 (P = 0.69).
The relative amount of polymeric antigen-specific IgA or
IgA 1 was expressed as the percentage of total antigen-specific
IgA or IgA 1 in each serum sample. Between the two groups
these percentages ofpolymeric IgA and IgAl antiinfluenza did
not differ (P = 0.09 and 0.30, respectively). The percentage of
polymeric IgA and IgA 1 antibodies appeared to decrease over
time after immunization (P = 0.06 for IgA and 0.01 for IgA 1).
Table I. Size Analysis ofthe Influenza-specific IgA and IgAl
in the Sera Obtained on Days 14 and 28 after Immunization
Day Patients (n = 16) Controls (n = 21)
Polymeric IgA antiinfluenza* 14 3.48±0.27 3.52±0.21
28 2.87±0.28 2.78±0.26
Polymeric IgAl 14 3.91±0.29 3.32±0.20
antiinfluenza 28 3.30±0.23 3.28±0.22
Monomeric IgA 14 4.25±0.26 4.25±0.23
antiinfluenza* 28 4.17±0.29 3.58±0.27
Monomeric IgAI 14 4.76±0.24 4.11±0.25
antiinfluenza 28 4.68±0.22 4.34±0.21
% Polymeric IgA/total IgAt 14 34.3±3.7 35.8±3.9
28 22.7±2.2 33.3±3.3
% Polymeric IgA I/total IgAI 14 31.6±4.0 32.5±2.5
28 21.7±2.5 26.9±2.3
Data are presented as mean±SEM.
* Natural logarithm of arbitrary units of influenza-specific antibodies.
* % Polymeric IgA/total IgA = ratio of influenza-specific polymeric
IgA to the sum of polymeric and monomeric influenza-specific IgA,
expressed as percentage.
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Discussion
The present study investigated whether patients with IgAN
have a selective IgAl hyperresponsiveness that could account
for the increase in the total serum IgA1 concentration (12-14),
the IgA 1-containing immune complexes (7, 15, 16), and the
IgAl deposits in the mesangium (2-8) previously found. Our
data, obtained after parenteral immunization with influenza
vaccine, show that the IgA hyperresponsiveness previously
suggested (28-30) was limited to the subclass IgAl. Patients
had significantly higher titers of IgAl antiinfluenza than con-
trols, and the peak of the immune response was reached at an
earlier time after vaccination. The IgM, IgG, and IgA2 re-
sponses were similar in patients and controls. The difference
between patients and controls in the total IgA immune re-
sponse to influenza virus was not statistically significant in our
study (P = 0.058). It would be interesting to investigate
whether a selective IgAl hyperresponsiveness, similar to the
findings in the present study, also occurs after a mucosal pre-
sentation of the antigen, simulating natural infections.
The study of the ratio of the antiinfluenza antibody iso-
types in the sera showed a significant increase in the IgA/IgG
ratio, and in the ratio of IgA to the total of the measured
influenza-specific antibodies IgA, IgG, and IgM in patients.
These data suggest that the hyperresponsiveness is not a gen-
eral phenomenon for all isotypes, but is limited to the IgA
class. Within the IgA class there was a significant shift toward
the IgA 1 isotype, as shown by the higher IgA 1 to total IgA
ratios in patients. A similar subclass shift toward IgA 1 has been
previously found in sera (12, 14), in the bone marrow (17), in
the tonsils (18), and in cultures of peripheral blood lympho-
cytes (14) from patients with IgAN. The present study shows
that this subclass shift is also demonstrable in an antigen-spe-
cific study. This is an important observation, since it sheds
light on the possible mechanism of the selective IgA 1 increase
in the sera of patients with IgAN. Theoretically, such an in-
crease could be the result of two different mechanisms. First,
patients with IgAN might be more heavily exposed, in fre-
quency or duration, to antigens that selectively induce an IgA 1
antibody response. That the IgA subclass produced may de-
pend on the type of antigen has been shown in several studies
(31-34). Another more attractive explanation is that patients
with IgAN have an abnormal regulation that causes them to
generate a high IgA 1 response to a wide variety of antigens
encountered by patients and healthy subjects alike. In view of
the overall increase of the IgA 1 serum levels in these patients
( 14), it is unlikely that this hyperresponsiveness is restricted to
a small number of antigens. The present study, in which an
arbitrarily chosen antigen was presented to patients and con-
trols, and which revealed a selective IgA 1 hyperresponsiveness,
favors the second theoretical explanation. More definite proof
of the hypothesis that patients with IgAN are hyperresponders
for IgAl will require that more antigens be investigated in a
similar way. Preferably, such future studies should include the
use of antigens that are known to induce a predominant IgA2
immune response, such as polysaccharides (34).
For the reasons mentioned above it is likely that a disorder
of immune regulation is responsible for the selective IgA I hy-
perresponsiveness in patients with IgAN. The mechanism of
this disorder is at present unclear. Little is known about the
regulation of the two subclasses of IgA, but from the available
data it is likely that there is independent regulation of both
subclasses (35). It is tempting to speculate about the role of ILs
in this respect, since it has been recently shown that ILs are
involved in the isotype regulation of the immune response
(36). IL-4 and -5 may play a role in the generation of an IgA
immune response (37-39), but the effect ofthese mediators on
the relative synthesis of the IgA subclasses is at present un-
known.
The pathogenetic significance of polymeric IgA in IgAN is
controversial. Conflicting data have been reported on the pres-
ence of polymeric IgA in the mesangial deposits (2, 5-8,
19-21). The present study gives no evidence that patients with
IgAN preferentially produce more polymeric IgA or IgAl anti-
bodies in response to influenza vaccination. Rather, a signifi-
cantly greater amount of monomeric IgA 1 antiinfluenza anti-
bodies were found. These data appear to confirm the recently
reported preponderance of monomeric IgAl in the circulating
immune complexes in IgAN (6, 16, 27). The percentage of
polymeric IgA and IgAl, produced in response to influenza
vaccination, is not significantly different in patients and con-
trols. This finding is in accord with many studies of the total
serum IgA and IgA 1 concentrations that demonstrate an in-
crease in polymers matched by an equal or larger increase in
monomers, with a resulting normal ratio of the two (6, 12, 13,
25, 26). In bone marrow of patients with IgAN we recently
have also found a normal ratio of polymeric to total IgA 1-pro-
ducing plasma cells and a normal percentage of polymeric
IgA 1 produced in cultures (40).
The considerable contribution of polymeric forms of IgA
and IgAl to the total immune response in these isotypes noted
in this study is not surprising in view ofthe recent literature on
this subject. The antigen-specific IgA induced in the serum was
found to be polymeric to a large extent, not only after mucosal
antigen presentation (31, 33), but also after systemic immuni-
zation or infection (34, 41-43). In some investigations it was
found that polymeric forms of IgA occurred especially in the
early immune response, and that the percentage of polymeric
antigen-specific IgA decreased at longer time intervals after the
presentation of antigen (41, 42). A decrease in the percentage
of polymeric IgA antiinfluenza in the course of time was also
noted in the present study, and this decrease appeared to be
more marked in the patient group.
In summary, the data indicate that patients with IgAN
have a higher than normal immune response to parenterally
administered inactivated influenza vaccine, limited to the
IgAl isotype. On the basis of previous studies (28-30), this
hyperresponsiveness does not appear to be limited to influ-
enza, but applies to various viral antigens. Therefore, the
hyperresponsiveness seems to be polyclonal in nature. Further
studies should elucidate whether this hyperresponsiveness is
due to a regulatory defect in these patients.
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